These authors contributed to the manuscript equally.
Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection
Article first published online: 7 OCT 2010
© 2010 The Japan Society of Hepatology
Volume 40, Issue 12, pages 1176–1187, December 2010
How to Cite
Nan, X., Shi, S., Yu, C. and Zhuang, H. (2010), Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection. Hepatology Research, 40: 1176–1187. doi: 10.1111/j.1872-034X.2010.00733.x
- Issue published online: 2 DEC 2010
- Article first published online: 7 OCT 2010
- Received 3 June 2010; revised 20 July 2010; accepted 19 August 2010.
- hepatitis C virus;
- hepatocellular carcinoma;
- liver cirrhosis
Aim: The impact of serological HBsAg− and anti-HBc+ on the prognosis of chronic hepatitis C virus (HCV) infection is unknown. We conducted a systematic review to analyze whether anti-HBc positivity imposes any effect on the course of HCV-related chronic liver disease.
Methods: We retrieved references from online databases that included PubMed and EMBASE. Data were gathered with regard to demographic information, disease progression and prognosis, and the results of serological tests. The development of hepatocellular carcinoma (HCC) was the endpoint of follow-up of all cohort studies.
Results: Eighteen references were included in this study, of which four were cohort studies. Twelve studies were retrospective, observational and non-interventional studies. According to our meta-analysis, the rate of serological HBsAg− and anti-HBc+ was higher among HCC patients compared with non-HCC patients (odds ratio [OR], 1.55; 95% CI, 1.22–1.98). HCV patients that were anti-HBc+ had a greater chance of developing HCC than their anti-HBc− counterparts (OR, 2.15; 95% CI, 1.34–3.47).
Conclusions: The serological status of HBsAg− and anti-HBc+ appears to be correlated with a poor prognosis for chronic HCV infection. Though the general quality of these references was low, and multiple confounding factors existed, the likelihood of a poorer outcome of HCV patients that are positive for anti-HBc should be considered by their physicians.